和络舒肝胶囊对慢性肝炎纤维化指标的影响

目的探讨中药和络舒肝胶囊对慢性肝炎患者血清ALT、CIV、HA、PCⅢ的影响。方法将237例慢性肝炎患者随机分为治疗组122例，对照组115例，两组患者均用护肝药、维生素等常规治疗方法，治疗组加服络舒肝胶囊6个月，分别于用药前及用药后第2月、第4月、第6月，检测血清中ALT、CIV、HA、PCⅢ的变化。结果治疗组与对照组相比用药后第2月ALT、CIV、HA、PCⅢ下降不明显（P〉0．05），但第4月与第6月均有明显下降（P〈0．05）。结论中药和络舒肝胶囊有明显的降低血清ALT、CIV、HA、PCⅢ的作用，是治疗慢性肝炎，防止肝纤维化的有效药物。

Clinical Effect on Early Hepatitis Cirrhosis Treated by Heluo Shugan Capsule

Objective To investigate the effect of Heluo Shugan capsule on serum ALT、CIV 、HA、PC Ⅲ of chronic hepatitis patients.Methods 237 patients of chronic hepatitis were divided at random into therapeutic group and control group.122 patients were treated by Heluo Shugan capsule for 6 months combination with routine protection liver drugs and 115 patients by routine protection liver drugs(contrast group).The level of serum ALT,CIV,HA and PC Ⅲ were determined before administration of the agents and 2、4、6 months after the treatment respectively.Results There was no significant difference between therapeutic group and control group in the level of of serum ALT、CIV、 HA and PCⅢ after 2 months treatment (P＞0.05),but declined obviously after 4 or 6 months (P＜0.05 ).Conclusion Heluo Shugan capsule has significant reducing effect on serum ALT、CIV、HA、PCⅢ.It is an effective drug for treating chronic hepatitis and preventing hepatic fibrosis.